Arkansas sues drugmakers, pharmacy benefit managers over insulin costs
Reuters
Published May 11, 2022 01:26PM ET
Updated May 11, 2022 04:50PM ET
By Brendan Pierson
(Reuters) -Arkansas's attorney general on Wednesday accused drugmakers and pharmacy benefit managers of colluding to drive up the price of insulin drugs, the latest in a series of lawsuits to take aim at skyrocketing costs for the life-sustaining medicine.
The lawsuit, filed in Pulaski County, Arkansas state court, targets Eli Lilly (NYSE:LLY) and Co, Novo Nordisk (NYSE:NVO) A/S and Sanofi (NASDAQ:SNY) SA, which together make the vast majority of the insulin drugs sold in the United States.
It also names the nation's leading pharmacy benefit managers (PBMs) - UnitedHealth Group Inc (NYSE:UNH)'s Optum unit, CVS Health Corp (NYSE:CVS)'s CVS Caremark and Cigna Corp (NYSE:CI)'s Express Scripts (NASDAQ:ESRX). PBMs maintain the lists of drugs covered by health insurance plans and negotiate prices with manufacturers.
Eli Lilly said in a statement that it was "disappointed" by "inaccurate claims" in the lawsuit and that it has voluntarily taken steps to ensure that patients can get its insulin for $35 per month or less.
The other defendants did not immediately respond to requests for comment.
Around 8.4 million of the 37 million people in the United States with diabetes use insulin drugs, according to the American Diabetes Association.
Prices of top-selling insulin products have soared in recent years. According to a 2021 Congressional report, Eli Lilly had raised the price of its Humalog 1,219% per vial since it launched, Novo Nordisk raised the price of NovoLog 627% since its introduction and Sanofi has raised the price of Lantus 715%.
Arkansas Attorney General Leslie Rutledge in Wednesday's lawsuit said that the PBMs, rather than negotiating lower prices on behalf of patients, have accepted higher prices in exchange for generous rebates from the drugmakers in order to enrich themselves, violating an Arkansas law against deceptive business practices.
Rutledge in a news conference said 50,000 Arkansans with diabetes were uninsured and that many had been forced to ration insulin because of the high cost.
Get The News You Want
Similar lawsuits brought by the state of Minnesota, city of Miami and groups of drug purchasers are already pending.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.